Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
2 October 2017 |
Main ID: |
EUCTR2014-000461-43-ES |
Date of registration:
|
04/11/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study comparing MHAA4549A in combination with oseltamivir versus placebo in combination with oseltamivir for the treatment of severe influenza A infection
|
Scientific title:
|
A PHASE 2 RANDOMIZED, DOUBLE-BLIND TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION |
Date of first enrolment:
|
17/11/2014 |
Target sample size:
|
334 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000461-43 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Belgium
|
Brazil
|
Bulgaria
|
Canada
|
Chile
|
Czech Republic
|
France
|
Germany
|
Hong Kong
|
Hungary
|
Italy
|
Korea, Republic of
|
Lithuania
|
Mexico
|
Netherlands
|
New Zealand
|
Peru
|
Poland
|
Singapore
|
South Africa
|
Spain
|
Sweden
|
United Kingdom
|
United States
| | | | | | |
Contacts
|
Name:
|
Trial Information Support Line-TISL
|
Address:
|
Grenzacherstrasse 124
4070
Basel
Switzerland |
Telephone:
|
+34913257300 |
Email:
|
spain.start_up_unit@roche.com |
Affiliation:
|
GENENTECH, Inc. c/o F.Hoffmann-La Roche Ltd |
|
Name:
|
Trial Information Support Line-TISL
|
Address:
|
Grenzacherstrasse 124
4070
Basel
Switzerland |
Telephone:
|
+34913257300 |
Email:
|
spain.start_up_unit@roche.com |
Affiliation:
|
GENENTECH, Inc. c/o F.Hoffmann-La Roche Ltd |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: ? Men or women >18 years of age
? Diagnosis of influenza A as determined by Sponsored-supplied rapid influenza test. If negative rapid influenza A test, a positive local molecular test (PCR) is required
? Requirement for oxygen supplementation to maintain SpO2 >92% or PPV within 24 hours of hospital admission
? Negative urine or serum pregnancy test for women of childbearing potential Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 200 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 134
Exclusion criteria: - Pregnant or lactating, or intending to become pregnant during the study
-Hypersensitivity to monoclonal antibodies or to the active substance or any excipients of MHAA4549A study drug.
-Hypersensitivity to the active susbtance or to any excipients of oseltamivir.
- Investigational therapy within 30 days prior to study treatment
- Received prior therapy with any anti-influenza monoclonal antibody therapy including MHAA4549A 8 months prior to study treatment
- Onset of influenza symptoms >5 days prior to study treatment
- Patients who have taken more than a total of 3 days (6 doses) of approved anti-influenza therapy (e.g., oral oseltamivir, inhaled zanamivir, or oral ribavirin) in the period from onset of symptoms and prior to enrollment
- Requiring home or baseline oxygenation therapy
- Positive influenza B or influenza A+B infection within 2 weeks prior to study treatment
- Admission >48 hours prior to study treatment
- Any disease or condition that would, in the opinion of the investigator or Sponsor, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Virus Diseases [C02]
|
Treatment of Influenza MedDRA version: 17.1
Level: LLT
Classification code 10022002
Term: Influenza A virus infection
System Organ Class: 100000004862
MedDRA version: 17.1
Level: LLT
Classification code 10022001
Term: Influenza (epidemic)
System Organ Class: 100000004862
MedDRA version: 17.1
Level: LLT
Classification code 10016790
Term: Flu
System Organ Class: 100000004862
|
Intervention(s)
|
Product Name: MHAA4549A Product Code: MHAA4549A/RO6876802 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: n.a. CAS Number: n.a. Current Sponsor code: MHAA4549A/RO6876802 Other descriptive name: [anti-Influenza A, 39.29] Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
Trade Name: Tamiflu Pharmaceutical Form: Capsule, hard INN or Proposed INN: OSELTAMIVIR PHOSPHATE CAS Number: 204255-11-8 Other descriptive name: OSELTAMIVIR PHOSPHATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75-
|
Primary Outcome(s)
|
Main Objective: to determine the time to normalization of respiratory function of patients dosed with MHAA4549A in combination with oseltamivir compared to patients dosed with placebo and oseltamivir.
|
Primary end point(s): Median time to normalization of respiratory function
|
Secondary Objective: ? To measure clinical failure after 24 hours post-infusion of study drug ? To determine the time to clinical resolution of vital signs ? To measure mortality in patients ? To determine changes in the extent and duration of viral shedding in upper respiratory samples ? To measure the duration of hospital and/or intensive care unit stay ? To measure antibiotic usage for respiratory indications ? To measure the frequency and severity of secondary complications of influenza ? To measure duration of positive pressure ventilation ? To measure readmission rates ? To characterize the PK profile of MHAA4549A in serum
|
Timepoint(s) of evaluation of this end point: The time to normalization of respiratory function will be defined as the time to removal of the patient from oxygen supplementation in order to maintain an oxygen saturation >95%. The analysis of this endpoint will be conducted at the end of the study after all patients have completed all study assessments and the database has been cleaned and closed.
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: All secondary endpoint analyses of the total study population will be conducted at the end of the study after all patients have completed all study assessments and the database has been cleaned and closed.
|
Secondary end point(s): ? Proportion of patients with clinical failure 24 hours post-infusion of study drug
? Median time to clinical normalization of vital signs
? Hazard ratio for mortality at Day 14 and Day 30
? Mean and median AUC of viral load
? Mean and median peak viral load
? Median duration of viral shedding in upper respiratory samples
? Median duration of hospitalization
? Median duration of ICU stay
? Proportion of patients requiring antibiotics for respiratory indications during study
? Proportion of patients with influenza secondary complications
? Median duration of ventilation
? Proportion of patients readmitted by Day 30
|
Secondary ID(s)
|
2014-000461-43-IT
|
GV29216
|
Source(s) of Monetary Support
|
GENENTECH, Inc. c/o F.Hoffmann-La Roche Ltd
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|